Results

1–4 of 4 results for dosing interval

Rapid Fluid Resolution With Aflibercept 8 mg May Be Associated With Extended Dosing Intervals at Week 96 in nAMD: A PULSAR Post Hoc Analysis
Michael W. Stewart, MD
Annual Meeting Talks
2025
Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2023
It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019